An FDA advisory panel said HIV/AIDS trials in adolescents may be appropriate in countries where adolescents are at higher risk for the disease, but said the risks may outweigh the benefits for testing in U.S. teens. The group is considering medical and ethical questions to improve research guidelines for testing a variety of therapies in clinical trials in children.

Full Story:

Related Summaries